JusticeItaly Official institution

Italy authorizes Paxfydos, a paclitaxel infusion powder from Sandoz

Italy's medicines agency AIFA has authorized Paxfydos, a paclitaxel powder for infusion, in a decision dated 20 October 2026. Sandoz S.p.A. holds the marketing authorization, and Kymos, S.L. in Spain is responsible for releasing batches. The medicine is hospital-only, and it is not yet assessed for reimbursement.

This summary was generated by AI; the official source prevails.

What does it mean?

Paxfydos is a cancer medicine given by drip into a vein, and it can now be sold in Italy. It is used only in hospitals or similar settings, not at a regular pharmacy.

Who is affected?

Hospitals, cancer patients who receive the infusion, and the companies that sell and supply it.